Brand Name

Gynazole 1

Generic Name
Butoconazole
View Brand Information
FDA approval date: April 29, 2015
Classification: Azole Antifungal
Form: Cream

What is Gynazole 1 (Butoconazole)?

GYNAZOLE 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is indicated for the local treatment of vulvovaginal candidiasis . The diagnosis should be confirmed by KOH smears and/or cultures. Note: GYNAZOLE, 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is safe and effective in non-pregnant women; however, the safety and effectiveness of this product in pregnant women has not been established.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Identifying novel aryl hydrocarbon receptor (AhR) modulators from clinically approved drugs: In silico screening and In vitro validation.
Identifying novel aryl hydrocarbon receptor (AhR) modulators from clinically approved drugs: In silico screening and In vitro validation.
Journal: Archives of biochemistry and biophysics
Published: February 22, 2024
The integrated stress response-related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability.
The integrated stress response-related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: April 06, 2023
Terconazole, an Azole Antifungal Drug, Increases Cytotoxicity in Antimitotic Drug-Treated Resistant Cancer Cells with Substrate-Specific P-gp Inhibitory Activity.
Terconazole, an Azole Antifungal Drug, Increases Cytotoxicity in Antimitotic Drug-Treated Resistant Cancer Cells with Substrate-Specific P-gp Inhibitory Activity.
Journal: International journal of molecular sciences
Published: September 29, 2022
View All Latest Advances